KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Shares Issued (2016 - 2021)

Halozyme Therapeutics (HALO) has disclosed Shares Issued for 12 consecutive years, with $4.3 million as the latest value for Q4 2021.

  • On a quarterly basis, Shares Issued fell 66.19% to $4.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was $12.5 million, a 80.22% decrease, with the full-year FY2022 number at $14.0 million, up 12.08% from a year prior.
  • Shares Issued was $4.3 million for Q4 2021 at Halozyme Therapeutics, down from $4.6 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $135.3 million in Q2 2017 to a low of -$127.2 million in Q3 2017.
  • A 5-year average of $5.8 million and a median of $4.4 million in 2019 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 16276.03% in 2017; the steepest drop was 24989.82% in 2017.
  • Halozyme Therapeutics' Shares Issued stood at $5.1 million in 2017, then plummeted by 59.47% to $2.1 million in 2018, then soared by 294.13% to $8.1 million in 2019, then skyrocketed by 56.78% to $12.7 million in 2020, then tumbled by 66.19% to $4.3 million in 2021.
  • Per Business Quant, the three most recent readings for HALO's Shares Issued are $4.3 million (Q4 2021), $4.6 million (Q3 2021), and $4.2 million (Q2 2021).